Anthracycline-based triplets do not improve the efficacy of platinum-fluoropyrimidine doublets in first-line treatment of advanced gastric cancer: real-world data from the AGAMEMON National Cancer Registry
Javier Gállego(Hospital General Universitario de Elche), Paula Cerdá(Hospital Quirón Teknon), A Rodríguez Palomo(Hospital Universitario Central de Asturias), Raquel Hernández(Hospital Municipal de Badalona), Carles Pericay(University Hospital Mútua de Terrassa), Monserrat Mangas(Hospital de Galdakao), Alberto Carmona‐Bayonas(Hospital General Universitario Morales Meseguer), María Luisa Limón(Sorbonne Université), Isabel Echavarría(Hospital General Universitario Gregorio Marañón), Juana María Cano(Complejo Hospitalario de Navarra), Carlos López(Ministerio de Salud Pública), Laura Visa(Hospital Del Mar), Paula Jiménez‐Fonseca(Hospital Universitario Central de Asturias), Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), Felipe Alvarez-Manceñido(Hospital General Universitario Morales Meseguer), José Eduardo Desiderio Lorenzo(Hospital Universitario de Canarias), Aitor Azkárate(Hospital Universitario Insular de Gran Canaria), Avinash Ramchandani(Hospital Universitario Insular de Gran Canaria), Elvira Buxó(Hospital Clínic de Barcelona), Teresa García(Hospital General Universitario Morales Meseguer), Ana Custodio(Hospital Universitario La Paz), Pablo Sala(Hospital Quirón Teknon), M. Ferrer-Cardona(Complejo Hospitalario de Navarra), Federico Longo(Instituto Cajal), A. Viúdez(Universidad Pública de Navarra (UPNA)), Manuel Sánchez Cánovas(Pontificia Universidad Católica de Chile), A. Lacalle(Hospital General Universitario Gregorio Marañón), A. Díaz-Serrano(Research Institute Hospital 12 de Octubre), Ana Fernández Montés(Instituto Cajal), Fernando Rivera(Samsung Medical Center)
Cited by 20
Related Papers
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
|The Lancet Oncology|2023|663
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial
|Nature Medicine|2023|541
Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer
|Breast Cancer Research|2014|254
Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer
|New England Journal of Medicine|2024|208